Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986340 |
| Trade Name | |
| Synonyms | BMS 986340|BMS986340 |
| Drug Descriptions |
BMS-986340 is a nonfucosylated monoclonal antibody that targets CCR8, with potential antitumor activity and ability to enhance antitumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 6694). |
| DrugClasses | CCR8 Antibody 13 |
| CAS Registry Number | NA |
| NCIT ID | C179913 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + BMS-986340 + Nivolumab + Trifluridine-tipiracil hydrochloride | BMS-986340 Bevacizumab Nivolumab Trifluridine-tipiracil hydrochloride | 0 | 1 |
| BMS-986340 | BMS-986340 | 0 | 1 |
| BMS-986340 + Docetaxel | BMS-986340 Docetaxel | 0 | 1 |
| BMS-986340 + Gemcitabine + Nab-paclitaxel + Nivolumab | BMS-986340 Gemcitabine Nab-paclitaxel Nivolumab | 0 | 1 |
| BMS-986340 + Nivolumab | BMS-986340 Nivolumab | 0 | 1 |